Global Recombinant Proteins Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Recombinant Proteins Market was valued at $5.2 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 9.2% CAGR, to an estimated market size of $8.1 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The recombinant proteins market comprises proteins generated through recombinant DNA (rDNA) technology, where specific gene sequences are cloned into expression vectors and produced in host systems such as bacteria, yeast, or mammalian cells. The scope includes proteins used as research reagents, diagnostic components, and GMP-grade raw materials for biopharmaceutical manufacturing, but excludes finished biologic drugs and vaccines produced via hybridoma techniques.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Recombinant Proteins Market in the period 2025-30:
- Integration of Artificial Intelligence and machine learning tools like AlphaFold is drastically reducing protein design timelines and optimizing expression yields.
- The rapid expansion of Cell and Gene Therapy (CGT) is driving massive demand for high-purity, GMP-grade cytokines and growth factors used in T-cell expansion.
- A significant shift toward Mammalian Cell Expression Systems, particularly CHO-based platforms, is occurring to ensure complex post-translational modifications required for human-like proteins.
- Rising prevalence of chronic diseases such as cancer and autoimmune disorders is fueling the need for recombinant proteins in drug discovery and biomarker research.
- The growing biosimilars market, spurred by patent expirations of major biologics, is creating a consistent demand for recombinant protein reference standards and reagents.
- Adoption of CRISPR/Cas9 genome editing is enabling the development of more stable and high-yielding host cell lines for commercial-scale protein production.
- Increased R&D investment from both government and private sectors is accelerating the transition from simple research reagents to specialized therapeutic candidates.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Cytokines & Growth Factors
- Enzymes
- Hormones
- Recombinant Antibodies
- Others